{ "disease": "ovarian-cancer", "label": "Ovarian cancer", "url": "https://usebiotransfer.org/disease/ovarian-cancer/", "built": "2026-09-12", "facts_hash": { "answers": "e59d641fbf55", "targets": "5deeae5c4138" }, "sources": { "targets": "Open Targets Platform GraphQL API v4", "trials": "ClinicalTrials.gov API v2" }, "retrieved": { "targets": "2026-09-12", "trials": "2026-09-12" }, "query": { "endpoint": "https://clinicaltrials.gov/api/v2/studies", "shape": "query.cond=&query.intr=&pageSize=200", "active_statuses": [ "ACTIVE_NOT_RECRUITING", "ENROLLING_BY_INVITATION", "NOT_YET_RECRUITING", "RECRUITING" ], "dedup": "by NCT id across synonyms", "study_types": "interventional counted in headline; observational reported separately", "known_floor": "trials naming an antigen only by product code are not retrieved by an intervention-name search" }, "targets": [ { "symbol": "TP53", "ensembl": "ENSG00000141510", "n_drug_entries": 9, "n_distinct_drugs": 8, "drugs": { "ALRIZOMADLIN": "PHASE_2", "CENERSEN": "PHASE_2", "CONTUSUGENE LADENOVEC": "PHASE_3", "EPRENETAPOPT": "PHASE_3", "IDASANUTLIN": "PHASE_3", "NAVTEMADLIN": "PHASE_3", "SIREMADLIN": "PHASE_2", "TEPRASIRAN": "PHASE_3" }, "approved": [], "n_approved": 0, "approved_for": {}, "tractability": [ { "modality": "SM", "bucket": "Advanced Clinical" }, { "modality": "SM", "bucket": "Structure with Ligand" }, { "modality": "SM", "bucket": "High-Quality Ligand" }, { "modality": "SM", "bucket": "Med-Quality Pocket" }, { "modality": "SM", "bucket": "Druggable Family" }, { "modality": "PR", "bucket": "UniProt Ubiquitination" }, { "modality": "PR", "bucket": "Database Ubiquitination" }, { "modality": "PR", "bucket": "Small Molecule Binder" }, { "modality": "OC", "bucket": "Advanced Clinical" } ] }, { "symbol": "BRCA1", "ensembl": "ENSG00000012048", "n_drug_entries": 0, "n_distinct_drugs": 0, "drugs": {}, "approved": [], "n_approved": 0, "approved_for": {}, "tractability": [ { "modality": "SM", "bucket": "Druggable Family" }, { "modality": "AB", "bucket": "GO CC high conf" }, { "modality": "PR", "bucket": "UniProt Ubiquitination" }, { "modality": "PR", "bucket": "Database Ubiquitination" }, { "modality": "PR", "bucket": "Small Molecule Binder" } ] }, { "symbol": "BRCA2", "ensembl": "ENSG00000139618", "n_drug_entries": 0, "n_distinct_drugs": 0, "drugs": {}, "approved": [], "n_approved": 0, "approved_for": {}, "tractability": [ { "modality": "SM", "bucket": "Structure with Ligand" }, { "modality": "PR", "bucket": "UniProt Ubiquitination" }, { "modality": "PR", "bucket": "Database Ubiquitination" } ] }, { "symbol": "CCNE1", "ensembl": "ENSG00000105173", "n_drug_entries": 0, "n_distinct_drugs": 0, "drugs": {}, "approved": [], "n_approved": 0, "approved_for": {}, "tractability": [ { "modality": "SM", "bucket": "Structure with Ligand" }, { "modality": "SM", "bucket": "High-Quality Ligand" }, { "modality": "SM", "bucket": "Druggable Family" }, { "modality": "PR", "bucket": "UniProt Ubiquitination" }, { "modality": "PR", "bucket": "Small Molecule Binder" } ] }, { "symbol": "FOLR1", "ensembl": "ENSG00000110195", "n_drug_entries": 4, "n_distinct_drugs": 4, "drugs": { "FARLETUZUMAB": "PHASE_3", "MIRVETUXIMAB": "PHASE_2", "MIRVETUXIMAB SORAVTANSINE": "APPROVAL", "VINTAFOLIDE": "APPROVAL" }, "approved": [ "MIRVETUXIMAB SORAVTANSINE", "VINTAFOLIDE" ], "n_approved": 2, "approved_for": { "MIRVETUXIMAB SORAVTANSINE": [ "ovarian cancer", "ovarian neoplasm", "fallopian tube neoplasm", "peritoneal neoplasm", "malignant epithelial tumor of ovary" ], "VINTAFOLIDE": [] }, "tractability": [ { "modality": "SM", "bucket": "Structure with Ligand" }, { "modality": "SM", "bucket": "High-Quality Ligand" }, { "modality": "AB", "bucket": "Advanced Clinical" }, { "modality": "AB", "bucket": "UniProt loc high conf" }, { "modality": "AB", "bucket": "UniProt SigP or TMHMM" }, { "modality": "AB", "bucket": "GO CC med conf" }, { "modality": "PR", "bucket": "Small Molecule Binder" }, { "modality": "OC", "bucket": "Approved Drug" } ] }, { "symbol": "MUC16", "ensembl": "ENSG00000181143", "n_drug_entries": 4, "n_distinct_drugs": 4, "drugs": { "ABAGOVOMAB": "PHASE_2_3", "IGOVOMAB": "APPROVAL", "OREGOVOMAB": "PHASE_3", "SOFITUZUMAB VEDOTIN": "PHASE_1" }, "approved": [ "IGOVOMAB" ], "n_approved": 1, "approved_for": { "IGOVOMAB": [ "radiologic finding", "ovarian neoplasm" ] }, "tractability": [ { "modality": "AB", "bucket": "Approved Drug" }, { "modality": "AB", "bucket": "GO CC high conf" }, { "modality": "AB", "bucket": "UniProt loc med conf" }, { "modality": "AB", "bucket": "UniProt SigP or TMHMM" }, { "modality": "PR", "bucket": "Database Ubiquitination" }, { "modality": "OC", "bucket": "Advanced Clinical" } ] }, { "symbol": "MSLN", "ensembl": "ENSG00000102854", "n_drug_entries": 5, "n_distinct_drugs": 5, "drugs": { "AMATUXIMAB": "PHASE_2", "ANETUMAB RAVTANSINE": "PHASE_2", "LMB-100": "PHASE_2", "RG-7600": "PHASE_1", "SS1(DSFV)-PE38": "PHASE_1_2" }, "approved": [], "n_approved": 0, "approved_for": {}, "tractability": [ { "modality": "AB", "bucket": "Advanced Clinical" }, { "modality": "AB", "bucket": "GO CC high conf" }, { "modality": "AB", "bucket": "UniProt loc med conf" }, { "modality": "AB", "bucket": "UniProt SigP or TMHMM" }, { "modality": "AB", "bucket": "Human Protein Atlas loc" }, { "modality": "PR", "bucket": "Database Ubiquitination" }, { "modality": "OC", "bucket": "Advanced Clinical" } ] }, { "symbol": "KRAS", "ensembl": "ENSG00000133703", "n_drug_entries": 3, "n_distinct_drugs": 3, "drugs": { "ADAGRASIB": "APPROVAL", "SALIRASIB": "PHASE_2", "SOTORASIB": "APPROVAL" }, "approved": [ "ADAGRASIB", "SOTORASIB" ], "n_approved": 2, "approved_for": { "ADAGRASIB": [ "non-small cell lung carcinoma" ], "SOTORASIB": [ "non-small cell lung carcinoma" ] }, "tractability": [ { "modality": "SM", "bucket": "Approved Drug" }, { "modality": "SM", "bucket": "Structure with Ligand" }, { "modality": "SM", "bucket": "High-Quality Ligand" }, { "modality": "AB", "bucket": "UniProt loc high conf" }, { "modality": "AB", "bucket": "GO CC high conf" }, { "modality": "PR", "bucket": "Literature" }, { "modality": "PR", "bucket": "UniProt Ubiquitination" }, { "modality": "PR", "bucket": "Database Ubiquitination" }, { "modality": "PR", "bucket": "Half-life Data" }, { "modality": "PR", "bucket": "Small Molecule Binder" } ] }, { "symbol": "ARID1A", "ensembl": "ENSG00000117713", "n_drug_entries": 0, "n_distinct_drugs": 0, "drugs": {}, "approved": [], "n_approved": 0, "approved_for": {}, "tractability": [ { "modality": "PR", "bucket": "Database Ubiquitination" }, { "modality": "PR", "bucket": "Half-life Data" } ] }, { "symbol": "PIK3CA", "ensembl": "ENSG00000121879", "n_drug_entries": 32, "n_distinct_drugs": 31, "drugs": { "ALPELISIB": "APPROVAL", "APITOLISIB": "PHASE_2", "AZD-6482": "UNKNOWN", "BAY-1082439": "PHASE_1", "BGT-226": "PHASE_1_2", "BUPARLISIB": "PHASE_3", "COPANLISIB": "APPROVAL", "DACTOLISIB": "PHASE_3", "DS-7423": "PHASE_1", "FIMEPINOSTAT": "PHASE_2", "GEDATOLISIB": "PHASE_3", "GSK-1059615": "PHASE_1", "INAVOLISIB": "APPROVAL", "IZORLISIB": "PHASE_1_2", "OMIPALISIB": "PHASE_1", "PANULISIB": "PHASE_1", "PAXALISIB": "PHASE_2_3", "PF-04691502": "PHASE_2", "PICTILISIB": "PHASE_2", "PILARALISIB": "PHASE_2", "PKI-179": "PHASE_1", "RECILISIB": "PHASE_1", "SAMOTOLISIB": "PHASE_2", "SERABELISIB": "PHASE_2", "SF-1126": "PHASE_2", "SONOLISIB": "PHASE_2", "TASELISIB": "PHASE_3", "VOXTALISIB": "PHASE_2", "VS-5584": "PHASE_1", "WX-037": "PHASE_1", "ZSTK-474": "PHASE_1" }, "approved": [ "ALPELISIB", "COPANLISIB", "INAVOLISIB" ], "n_approved": 3, "approved_for": { "ALPELISIB": [ "breast cancer", "breast neoplasm", "breast carcinoma" ], "COPANLISIB": [ "follicular lymphoma", "non-Hodgkin lymphoma", "neoplasm of mature B-cells" ], "INAVOLISIB": [ "breast neoplasm" ] }, "tractability": [ { "modality": "SM", "bucket": "Approved Drug" }, { "modality": "SM", "bucket": "Structure with Ligand" }, { "modality": "SM", "bucket": "High-Quality Ligand" }, { "modality": "SM", "bucket": "High-Quality Pocket" }, { "modality": "SM", "bucket": "Druggable Family" }, { "modality": "AB", "bucket": "GO CC med conf" }, { "modality": "PR", "bucket": "Literature" }, { "modality": "PR", "bucket": "Database Ubiquitination" }, { "modality": "PR", "bucket": "Half-life Data" }, { "modality": "PR", "bucket": "Small Molecule Binder" } ] }, { "symbol": "PTEN", "ensembl": "ENSG00000171862", "n_drug_entries": 0, "n_distinct_drugs": 0, "drugs": {}, "approved": [], "n_approved": 0, "approved_for": {}, "tractability": [ { "modality": "SM", "bucket": "Structure with Ligand" }, { "modality": "AB", "bucket": "UniProt loc high conf" }, { "modality": "AB", "bucket": "GO CC high conf" }, { "modality": "PR", "bucket": "UniProt Ubiquitination" }, { "modality": "PR", "bucket": "Database Ubiquitination" }, { "modality": "PR", "bucket": "Half-life Data" }, { "modality": "PR", "bucket": "Small Molecule Binder" } ] }, { "symbol": "NF1", "ensembl": "ENSG00000196712", "n_drug_entries": 0, "n_distinct_drugs": 0, "drugs": {}, "approved": [], "n_approved": 0, "approved_for": {}, "tractability": [ { "modality": "SM", "bucket": "Structure with Ligand" }, { "modality": "SM", "bucket": "High-Quality Pocket" }, { "modality": "AB", "bucket": "UniProt loc high conf" }, { "modality": "AB", "bucket": "GO CC high conf" }, { "modality": "AB", "bucket": "Human Protein Atlas loc" }, { "modality": "PR", "bucket": "UniProt Ubiquitination" }, { "modality": "PR", "bucket": "Database Ubiquitination" }, { "modality": "PR", "bucket": "Half-life Data" } ] } ], "trials": { "by_antigen": { "FRalpha": { "n": 69, "n_observational": 14, "n_active": 30, "n_withdrawn": 2, "trials": [ { "nct": "NCT04300556", "title": "A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FR\u03b1)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types", "status": "RECRUITING", "last_update": "2026-06-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04606914", "title": "Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer", "status": "RECRUITING", "last_update": "2026-07-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05579366", "title": "Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)", "status": "RECRUITING", "last_update": "2026-08-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05887609", "title": "An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib", "status": "RECRUITING", "last_update": "2026-07-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05920798", "title": "Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer", "status": "RECRUITING", "last_update": "2026-04-06", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06216496", "title": "Evaluation of Amino Acid Metabolism Changes in Ovarian Cancer", "status": "RECRUITING", "last_update": "2024-05-20", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06400472", "title": "A Study of Sofe-M in Participants With Selected Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-09-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06547840", "title": "A Study of MOv18 IgE in Patients With Solid Tumours That Express Folate Receptor Alpha", "status": "RECRUITING", "last_update": "2026-04-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06639074", "title": "Folate Receptor Alpha Dendritic Cells (FR\u03b1DCs) or Placebo for the Treatment of Patients With Stage III or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, FAROUT Trial", "status": "RECRUITING", "last_update": "2025-10-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06682988", "title": "A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine", "status": "RECRUITING", "last_update": "2026-05-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06890338", "title": "A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FR\u03b1)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.", "status": "RECRUITING", "last_update": "2026-09-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06976892", "title": "Investigating Idetrexed and Olaparib in Patients With Ovarian Cancer", "status": "RECRUITING", "last_update": "2025-08-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07059845", "title": "A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer", "status": "RECRUITING", "last_update": "2026-08-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07213804", "title": "A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer", "status": "RECRUITING", "last_update": "2026-09-08", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07218809", "title": "AZD5335 vs. Mirvetuximab Soravtansine in FR\u03b1-high and AZD5335 vs. Chemotherapy in FR\u03b1-low Platinum-resistant Ovarian Cancer", "status": "RECRUITING", "last_update": "2026-07-21", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07480954", "title": "Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FR\u03b1, MUC16)", "status": "RECRUITING", "last_update": "2026-03-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07604766", "title": "An Extension Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer in China", "status": "RECRUITING", "last_update": "2026-09-09", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07617753", "title": "Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FR\u03b1, MUC16) pt2", "status": "RECRUITING", "last_update": "2026-06-01", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07690189", "title": "Study of NTB-928 in R/R OC", "status": "RECRUITING", "last_update": "2026-08-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00055432", "title": "Gemzar (Gemcitabine) and Alimta (Pemetrexed) in the Treatment of Patients With Recurrent Platinum-Sensitive and Platinum-Resistant Ovarian or Peritoneal Cancer", "status": "TERMINATED", "last_update": "2006-09-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00155935", "title": "The Development of Human Immunologic Assays Specific to Folate Receptor Antigen", "status": "UNKNOWN", "last_update": "2007-08-13", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00417144", "title": "Comparison Between GnRH Agonist and GnRH Antagonist Protocols of Ovarian Stimulation in PCOS Patients", "status": "UNKNOWN", "last_update": "2006-12-29", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00517621", "title": "Use of FACT-GOG/NTX Questionnaire in Peripheral Neurotoxicity & Validation of a French Version of This Questionnaire", "status": "COMPLETED", "last_update": "2011-02-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01511055", "title": "Intra-op Detection of Occult Ovarian Carcinoma Using a Folate-Alpha Receptor Specific Fluorescent Ligand", "status": "TERMINATED", "last_update": "2020-11-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01606241", "title": "Vaccine Therapy and Cyclophosphamide in Treating Patients With Stage II-III Breast or Stage II-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer", "status": "COMPLETED", "last_update": "2024-08-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01609556", "title": "First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Mirvetuximab Soravtansine in Adults With Ovarian Cancer and Other Folate Receptor 1 (FOLR1)-Positive Solid Tumors", "status": "COMPLETED", "last_update": "2021-02-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02111941", "title": "Vaccine Therapy for Patients With Stage IIIC-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer", "status": "COMPLETED", "last_update": "2025-10-31", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02317705", "title": "Phase 2 Study of OTL38 for Intra-operative Imaging of Folate Receptor-alpha Positive Ovarian Cancer", "status": "COMPLETED", "last_update": "2022-06-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02520115", "title": "Folate Receptor in Diagnosing Ovarian Cancer Using Serum Samples From Patients With Newly Diagnosed Pelvic Mass or Previously Diagnosed Ovarian Cancer", "status": "COMPLETED", "last_update": "2019-08-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02598219", "title": "Evaluation of Sentinel Node Policy in Early Stage Endometrial Carcinomas at Intermediate and High Risk of Recurrence.", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-18", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02606305", "title": "Study of Mirvetuximab Soravtansine in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin in Participants With Folate Receptor Alpha (FR\u03b1) Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal, or Fallopian Tube Cancer", "status": "COMPLETED", "last_update": "2024-06-14", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02631876", "title": "A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer", "status": "COMPLETED", "last_update": "2020-10-14", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02764333", "title": "TPIV200/huFR-1 (A Multi-Epitope Anti-Folate Receptor Vaccine) Plus Anti-PD-L1 MEDI4736 (Durvalumab) in Patients With Platinum Resistant Ovarian Cancer", "status": "COMPLETED", "last_update": "2021-11-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02978222", "title": "Folate Receptor Alpha Peptide Vaccine With GM-CSF Versus GM-CSF Alone in Patients With Platinum Sensitive Ovarian Cancer", "status": "TERMINATED", "last_update": "2022-12-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02996825", "title": "Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients With FRalpha-Positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial, or Triple Negative Breast Cancer", "status": "COMPLETED", "last_update": "2024-04-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03180307", "title": "OTL38 for Intra-operative Imaging of Folate Receptor Positive Ovarian Cancer", "status": "COMPLETED", "last_update": "2022-02-04", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03242993", "title": "[18F]-AZAFOL AS POSITRON EMISSION TOMOGRAPHY (PET) TRACER in FR Positive Cancer Imaging", "status": "COMPLETED", "last_update": "2020-02-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03386942", "title": "A Study of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin) in Participants With Solid Tumors", "status": "COMPLETED", "last_update": "2022-11-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03552471", "title": "Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer", "status": "COMPLETED", "last_update": "2025-02-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03585764", "title": "MOv19-BBz CAR T Cells in aFR Expressing Recurrent High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer", "status": "TERMINATED", "last_update": "2025-03-26", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03748186", "title": "Study of STRO-002, an Anti-Folate Receptor Alpha (FolR\u03b1) Antibody Drug Conjugate in Ovarian & Endometrial Cancers", "status": "COMPLETED", "last_update": "2025-08-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03752216", "title": "NIraparib and Quality of LifE is a Longitudinal Study Evaluating in Real Life the Tolerability of Niraparib.", "status": "COMPLETED", "last_update": "2024-12-13", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03773263", "title": "New Application of Sequential in Vitro Muturation System for Infertility Patients With Polycystic Ovary Syndrome", "status": "UNKNOWN", "last_update": "2018-12-12", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04209855", "title": "A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FR\u03b1) Expression", "status": "COMPLETED", "last_update": "2025-08-27", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04274426", "title": "Mirvetuximab Soravtansine (IMGN853), in Folate Receptor Alpha (FR\u03b1) High Recurrent Ovarian Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04289805", "title": "Controlled Ovarian Stimulation in Newly Diagnosed Breast Cancer PatiEnts (fAMHOPE)", "status": "TERMINATED", "last_update": "2025-01-31", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04296890", "title": "A Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression", "status": "COMPLETED", "last_update": "2024-08-07", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04610957", "title": "Effect of Adding Isoflavonoids to Clomiphene Citrate for Ovulation Induction in Women With Polycystic Ovary Syndrome", "status": "COMPLETED", "last_update": "2020-11-02", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04941378", "title": "OTL38 Injection (OTL38) for Intra-Operative Imaging of Folate Receptor Positive Ovarian Cancer", "status": "WITHDRAWN", "last_update": "2022-06-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05001282", "title": "A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FR\u03b1)", "status": "TERMINATED", "last_update": "2024-08-07", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05041257", "title": "Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Peritoneal, and Fallopian Tube Cancers", "status": "COMPLETED", "last_update": "2026-01-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05200364", "title": "A Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Epithelial Ovarian Cancer", "status": "TERMINATED", "last_update": "2025-09-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05397093", "title": "ITIL-306 in Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2026-04-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05445778", "title": "Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-02", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05456685", "title": "Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FR\u03b1) Expressing, Platinum-sensitive Epithelial Ovarian Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-10-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05483933", "title": "Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian Cancers", "status": "COMPLETED", "last_update": "2025-12-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05498597", "title": "AMT-151 in Patients With Selected Advanced Solid Tumours", "status": "UNKNOWN", "last_update": "2023-10-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05613088", "title": "A Study of MORAb-202 Versus Investigator's Choice Chemotherapy in Female Participants With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer", "status": "COMPLETED", "last_update": "2026-04-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05622890", "title": "A Single-arm Clinical Trial of IMGN853 in Chinese Adult Patients With Platinum-resistant, Epithelial Ovarian Cancer", "status": "UNKNOWN", "last_update": "2022-11-21", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05870748", "title": "REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1", "status": "TERMINATED", "last_update": "2025-09-23", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06339567", "title": "Evaluation of the Venous Thrombotic Biological Profile of Different PCOS Phenotypes: French Cross-sectional Study", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-18", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06365853", "title": "A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06376253", "title": "A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers", "status": "TERMINATED", "last_update": "2026-07-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06390995", "title": "A Study of TAK-853 in Adult Participants With Folate Receptor Alpha-Positive Advanced Ovarian Cancer And Other Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-16", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06545617", "title": "A Clinical Study to Observe How Well That BAT8006 Works on Patients With Platinum Resistance Ovarian Cancer", "status": "WITHDRAWN", "last_update": "2026-01-07", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06619236", "title": "Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-09", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07741630", "title": "Mirvetuximab Soravtansine Combined With Suvemcitug in Platinum-Resistant Recurrent Ovarian Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07778498", "title": "A Phase I/II, First-in-Human Study to Evaluate TJ102 in Participants With Advanced or Metastatic Ovarian Cancer and Other Solid Tumors.", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07790939", "title": "89Zr-DFO-Mirvetuximab PET/CT Imaging for Companion Diagnosis and Response Evaluation in Ovarian Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-27", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" } ], "cell_therapy": { "n": 3, "n_observational": 0, "n_active": 2, "n_withdrawn": 0, "trials": [ { "nct": "NCT07480954", "title": "Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FR\u03b1, MUC16)", "status": "RECRUITING", "last_update": "2026-03-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07617753", "title": "Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FR\u03b1, MUC16) pt2", "status": "RECRUITING", "last_update": "2026-06-01", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03585764", "title": "MOv19-BBz CAR T Cells in aFR Expressing Recurrent High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer", "status": "TERMINATED", "last_update": "2025-03-26", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "synonyms_searched": [ "folate receptor alpha", "FR\u03b1", "FRa", "FOLR1", "mirvetuximab", "Elahere", "luveltamab" ] }, "CA-125": { "n": 65, "n_observational": 29, "n_active": 24, "n_withdrawn": 4, "trials": [ { "nct": "NCT00539162", "title": "Use of CA125 and Complementary Biomarkers for the Early Detection of Ovarian Cancer in Low Risk Women", "status": "RECRUITING", "last_update": "2026-05-06", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03564340", "title": "Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers", "status": "RECRUITING", "last_update": "2026-09-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04590326", "title": "A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab", "status": "RECRUITING", "last_update": "2026-08-20", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04811703", "title": "Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Associated With Systemic Chemotherapy in Women With Advanced Ovarian Cancer", "status": "RECRUITING", "last_update": "2026-05-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04891029", "title": "Early Detection of Endometrial/Ovarian Cancer and Hereditary Predisposition of These Cancers", "status": "RECRUITING", "last_update": "2025-06-17", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05080556", "title": "Adaptive ChemoTherapy for Ovarian Cancer in Patients With Replased Platinum-sensitive High Grade Serous or High Grade Endometrioid Ovarian Cancer", "status": "RECRUITING", "last_update": "2024-04-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06232122", "title": "Evaluation of 68Ga-FAPI-46 and 18F-FDG PET/CT Imaging for Detecting Recurrent Tumor Lesions in Patients of Ovarian Cancer", "status": "RECRUITING", "last_update": "2024-01-30", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06469281", "title": "A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers", "status": "RECRUITING", "last_update": "2026-02-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06787612", "title": "Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer", "status": "RECRUITING", "last_update": "2026-08-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06883409", "title": "Laparoscopic Interval Cytoreductive Surgery in Advance Ovarian Cancer", "status": "RECRUITING", "last_update": "2025-03-26", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07022535", "title": "Personalised Timing of Interval Debulking Surgery in Advanced Ovarian Cancer", "status": "RECRUITING", "last_update": "2025-07-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07023484", "title": "Personalized Timing of Interval Debulking Surgery in Advanced Ovarian Cancer", "status": "RECRUITING", "last_update": "2025-07-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07470853", "title": "A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.", "status": "RECRUITING", "last_update": "2026-08-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07480954", "title": "Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FR\u03b1, MUC16)", "status": "RECRUITING", "last_update": "2026-03-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07489287", "title": "GB-5267 for the Treatment Platinum-Resistant Ovarian, Peritoneal, or Fallopian Tube Cancer", "status": "RECRUITING", "last_update": "2026-06-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07617753", "title": "Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FR\u03b1, MUC16) pt2", "status": "RECRUITING", "last_update": "2026-06-01", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00002895", "title": "Early Chemotherapy Based on CA 125 Level Alone Compared With Delayed Chemotherapy in Treating Patients With Recurrent Ovarian Epithelial , Fallopian Tube, or Primary Peritoneal Cancer", "status": "COMPLETED", "last_update": "2013-12-04", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00003634", "title": "Monoclonal Antibody Therapy in Treating Patients With Residual Disease From Stage III or Stage IV Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer Following Surgery and Chemotherapy", "status": "UNKNOWN", "last_update": "2013-11-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00004064", "title": "Monoclonal Antibody Therapy in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal Cancer", "status": "UNKNOWN", "last_update": "2013-11-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00034138", "title": "A Comparative Pharmacokinetics and Safety Study of OvaRex MAb-B43.13 in Patients With Ovarian Epithelial Carcinoma", "status": "TERMINATED", "last_update": "2007-12-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00034372", "title": "Multicenter Clinical Trial of Intravenous OvaRex MAb-B43.13 as Post-Chemotherapy Consolidation for Ovarian Carcinoma", "status": "TERMINATED", "last_update": "2007-12-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00039559", "title": "Clinical Trial to Screen Participants Who Are at High Genetic Risk for Ovarian Cancer", "status": "UNKNOWN", "last_update": "2013-06-10", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00050375", "title": "Clinical Trial for Ovarian Cancer (OvaRex\u00ae)", "status": "TERMINATED", "last_update": "2007-12-18", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00058032", "title": "CA125 and Ultrasound in Detecting Ovarian Cancer in Postmenopausal Women", "status": "COMPLETED", "last_update": "2020-11-19", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00083928", "title": "Efficacy of \u00c56 in Ovarian Cancer Patients Following First-Line Chemotherapy and a Rising CA125 Levels", "status": "COMPLETED", "last_update": "2013-01-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00086632", "title": "Study of Ovarex\u00ae (Oregovomab) MAb With Front-Line Chemotherapy for Ovarian Cancer Treatment", "status": "TERMINATED", "last_update": "2007-12-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00305838", "title": "CA 125 Levels in Treating Patients With Relapsed Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Who Are Receiving Tamoxifen", "status": "UNKNOWN", "last_update": "2013-08-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00442598", "title": "Safety and Efficacy Study of Glufosfamide in Ovarian Cancer", "status": "TERMINATED", "last_update": "2015-03-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00551265", "title": "Oregovomab With or Without Cyclophosphamide in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Responded to Second-Line Chemotherapy", "status": "WITHDRAWN", "last_update": "2017-07-14", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00587093", "title": "A Multicenter Trial On The Utility and Impact Of Computed Tomography and Serum CA-125 In the Management of Newly Diagnosed Ovarian Cancer", "status": "COMPLETED", "last_update": "2018-02-22", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00620243", "title": "Pilot Study to Evaluate 18F-fluorodeoxyglucose (FDG) Positron Emission Tomography /Computed Tomography (PET/CT) in Prediction of Early Response to Chemotherapy in Ovarian Cancer.", "status": "COMPLETED", "last_update": "2012-01-09", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00926107", "title": "Study of the mTOR Inhibitor Temsirolimus (CCI-779) to Treat Ovarian Cancer With CA125 Only Relapse", "status": "TERMINATED", "last_update": "2011-11-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01004380", "title": "Safety Study of Farletuzumab, Carboplatin and Pegylated Liposomal Doxorubicin (PLD) to Treat Platinum-sensitive Ovarian Cancer", "status": "COMPLETED", "last_update": "2014-07-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01111903", "title": "A 2 Stage Trial of Lenalidomide (REV) in Asymptomatic Ovarian Cancer Patients With Increasing CA 125 in Late Relapse", "status": "COMPLETED", "last_update": "2016-03-17", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01121640", "title": "A Trial Using Novel Markers to Predict Malignancy in Elevated-Risk Women", "status": "COMPLETED", "last_update": "2018-12-13", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01133756", "title": "E7080 in Combination With Carboplatin + Gemcitabine Versus Carboplatin + Gemcitabine Alone as Second Line Therapy in Patients With Platinum-Sensitive Recurrent Ovarian Cancer by CA125", "status": "TERMINATED", "last_update": "2023-06-22", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01146795", "title": "Neoadjuvant Therapy for Ovarian Cancer", "status": "COMPLETED", "last_update": "2021-02-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01292733", "title": "Cancer Screening Program for Women at High Risk for Developing Ovarian Cancer", "status": "TERMINATED", "last_update": "2016-01-20", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01616303", "title": "A Controlled Study of the Effectiveness of Oregovomab (Antibody) Plus Chemotherapy in Advanced Ovarian Cancer", "status": "COMPLETED", "last_update": "2020-09-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01685255", "title": "A Phase 2 Study of the IDO Inhibitor Epacadostat Versus Tamoxifen for Subjects With Biochemical-recurrent-only EOC, PPC or FTC Following Complete Remission With First-line Chemotherapy", "status": "TERMINATED", "last_update": "2019-03-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01696994", "title": "Screening for Ovarian Cancer in Older Patients (PLCO Screening Trial)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-24", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01907789", "title": "Prophylactic Salpingectomy With Delayed Oophorectomy", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-16", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02289950", "title": "A Study to Assess the Efficacy and Safety of Farletuzumab (MORAb 003) in Combination With Carboplatin Plus Paclitaxel or Carboplatin Plus Pegylated Liposomal Doxorubicin (PLD) in Participants With Low CA125 Platinum-sensitive Ovarian Cancer", "status": "COMPLETED", "last_update": "2021-09-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02298855", "title": "Individualised Versus Conventional Medical Follow-up for Women After Primary Treatment for Ovarian Cancer.", "status": "COMPLETED", "last_update": "2014-11-24", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02392676", "title": "Olaparib Maintenance Treatment Versus Placebo in Patients With PSR Ovarian Cancer Who Are in CR or PR to Platinum-based Chemotherapy and Whose Tumours Carry sBRCAm or HRR-associated Genes Mutations", "status": "WITHDRAWN", "last_update": "2016-05-02", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02432690", "title": "A Study of BBI503 in Asymptomatic Recurrent Ovarian Cancer Patients With CA-125 Elevation", "status": "TERMINATED", "last_update": "2023-11-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02441140", "title": "Detection of Tumor Associated Cell-free DNA in Peritoneal Fluid Obtained by Culdocentesis", "status": "TERMINATED", "last_update": "2020-05-04", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02595281", "title": "HE4 as a Relapse Biomarker in Ovarian Cancers", "status": "COMPLETED", "last_update": "2022-12-19", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02948426", "title": "Intraperitoneal Infusion of Autologous Monocytes With Sylatron (Peginterferon Alfa-2b) and Actimmune (Interferon Gamma-1b) in Women With Recurrent or Refractory Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer", "status": "TERMINATED", "last_update": "2026-01-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03100006", "title": "Phase Ib/IIa Trial to Evaluate Oregovomab and Nivolumab in Epithelial Cancer of Ovarian, Tubal or Peritoneal Origin", "status": "TERMINATED", "last_update": "2022-06-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03162562", "title": "The Safety and Antitumor Activity of the Combination of Oregovomab and Hiltonol in Recurrent Advanced Ovarian Cancer", "status": "TERMINATED", "last_update": "2020-12-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03979339", "title": "Feasibility of a New Technology for Isolating Circulating Tumour Cells", "status": "UNKNOWN", "last_update": "2021-10-13", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04377087", "title": "Delayed Initiation of Olaparib Maintenance Therapy in Platinum Sensitive Recurrent Ovarian Cancer", "status": "TERMINATED", "last_update": "2024-08-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04498117", "title": "Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-01", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04620954", "title": "Clinical Trial of Chemotherapy, Oregovomab and Nivolumab in Patients With Epithelial Cancer of Ovarian, Tubal or Peritoneal Origin", "status": "UNKNOWN", "last_update": "2021-12-01", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04826029", "title": "Impact of Systematic Imaging for Follow up of Patients With Ovarian, Fallopian Tube or Primary Peritoneum Cancer", "status": "WITHDRAWN", "last_update": "2021-12-10", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04938583", "title": "Oregovomab in Combination With Bevacizumab Plus Chemo in BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-06", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05311579", "title": "Niraparib Plus Anlotinib for Recurrent Ovarian Cancer", "status": "UNKNOWN", "last_update": "2022-04-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05335993", "title": "A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05407584", "title": "Oregovomab and PLD in PARP Inhibitor Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment", "status": "UNKNOWN", "last_update": "2023-05-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05605535", "title": "Oregovomab Plus Chemotherapy in Neo-adjuvant Setting in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05991752", "title": "Health-Economic Evaluation of Early Diagnosis of Epithalial Ovarian Cancer Recurrence Using the ROMA Score: a Prospective Multicenter Randomized Trial", "status": "WITHDRAWN", "last_update": "2026-06-11", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07295132", "title": "RESCUE Study (REcurrent Ovarian Cancer Secondary Cytoreduction Using Chemotherapy rEsponse)", "status": "NOT_YET_RECRUITING", "last_update": "2025-12-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07637851", "title": "Safety and Efficacy of Ubamatamab With First-line Chemotherapy in Ovarian Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-10", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07684846", "title": "Longitudinal Plasma Proteomic Remodeling in Ovarian Cancer", "status": "COMPLETED", "last_update": "2026-07-06", "phase": "NA", "study_type": "INTERVENTIONAL" } ], "cell_therapy": { "n": 3, "n_observational": 1, "n_active": 3, "n_withdrawn": 0, "trials": [ { "nct": "NCT06469281", "title": "A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers", "status": "RECRUITING", "last_update": "2026-02-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07480954", "title": "Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FR\u03b1, MUC16)", "status": "RECRUITING", "last_update": "2026-03-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07617753", "title": "Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FR\u03b1, MUC16) pt2", "status": "RECRUITING", "last_update": "2026-06-01", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ] }, "synonyms_searched": [ "CA-125", "CA125", "MUC16", "oregovomab", "ubamatamab" ] }, "mesothelin": { "n": 37, "n_observational": 4, "n_active": 16, "n_withdrawn": 0, "trials": [ { "nct": "NCT05403554", "title": "A Study of NI-1801 in Patients with Mesothelin Expressing Solid Cancers", "status": "RECRUITING", "last_update": "2024-10-29", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05410717", "title": "CLDN6/GPC3/Mesothelin/AXL-CAR-NK Cell Therapy for Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2024-06-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05568680", "title": "SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma", "status": "RECRUITING", "last_update": "2026-06-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06051695", "title": "A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression", "status": "RECRUITING", "last_update": "2026-06-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06562647", "title": "SY001 Targets Mesothelin in a Single-arm, Dose-increasing Setting in Subjects With Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-02-13", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06756035", "title": "CT-95 in Advanced Cancers Associated With Mesothelin Expression", "status": "RECRUITING", "last_update": "2026-06-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06885697", "title": "Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma", "status": "RECRUITING", "last_update": "2026-08-26", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07030907", "title": "A Study to Evaluate the Safety and Efficacy of OPB-101 in Platinum-resistant Ovarian Cancer", "status": "RECRUITING", "last_update": "2025-12-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07480954", "title": "Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FR\u03b1, MUC16)", "status": "RECRUITING", "last_update": "2026-03-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07523529", "title": "Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-04-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07589543", "title": "Dual-Target CAR-NK Cells in Recurrent or Refractory Epithelial Ovarian Cancer", "status": "RECRUITING", "last_update": "2026-05-15", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07617753", "title": "Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FR\u03b1, MUC16) pt2", "status": "RECRUITING", "last_update": "2026-06-01", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00006981", "title": "Immunotoxin Therapy in Treating Patients With Advanced Cancer", "status": "COMPLETED", "last_update": "2015-04-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00066651", "title": "Immunotoxin Therapy in Treating Patients With Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2015-04-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00325494", "title": "A Study of MORAb-009 in Subjects With Pancreatic Cancer, Mesothelioma, or Certain Types of Ovarian or Lung Cancer", "status": "COMPLETED", "last_update": "2014-07-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00585845", "title": "Study of Safety and Tolerability of Intravenous CRS-207 in Adults With Selected Advanced Solid Tumors Who Have Failed or Who Are Not Candidates for Standard Treatment", "status": "TERMINATED", "last_update": "2009-02-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01413451", "title": "Amatuximab for High Mesothelin Cancers", "status": "TERMINATED", "last_update": "2019-12-17", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01521325", "title": "A Single-Dose Pilot Study of Radiolabeled Amatuximab (MORAb-009) in Mesothelin Over Expressing Cancers", "status": "COMPLETED", "last_update": "2016-09-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01583686", "title": "CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer", "status": "TERMINATED", "last_update": "2019-10-14", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02159716", "title": "CART-meso in Mesothelin Expressing Cancers", "status": "COMPLETED", "last_update": "2025-06-29", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02485119", "title": "Phase I Dose Escalation Study of BAY94-9343 Given by Intravenous Infusion Every 3 Weeks in Japanese Subjects With Advanced Malignancies", "status": "COMPLETED", "last_update": "2018-06-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02580747", "title": "Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART-meso", "status": "UNKNOWN", "last_update": "2015-10-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02751918", "title": "Phase Ib Study of Anetumab Ravtansine in Combination With Pegylated Liposomal Doxorubicin in Patients With Recurrent Mesothelin-expressing Platinum-resistant Cancer", "status": "COMPLETED", "last_update": "2019-11-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03054298", "title": "CAR T Cells in Mesothelin Expressing Cancers", "status": "COMPLETED", "last_update": "2025-04-29", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03507452", "title": "First-in-human Study of BAY2287411 Injection, a Thorium-227 Labeled Antibody-chelator Conjugate, in Patients With Tumors Known to Express Mesothelin", "status": "COMPLETED", "last_update": "2023-03-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03587311", "title": "Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03608618", "title": "Intraperitoneal MCY-M11 (Mesothelin-targeting CAR) for Treatment of Advanced Ovarian Cancer and Peritoneal Mesothelioma", "status": "TERMINATED", "last_update": "2021-09-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03692637", "title": "Study of Anti-Mesothelin Car NK Cells in Epithelial Ovarian Cancer", "status": "UNKNOWN", "last_update": "2019-01-31", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03907852", "title": "Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-08-27", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04503980", "title": "\u03b1PD1-MSLN-CAR T Cells for the Treatment of MSLN-positive Advanced Solid Tumors", "status": "UNKNOWN", "last_update": "2020-08-07", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04562298", "title": "A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of LCAR-M23, a CAR-T Cell Therapy Targeting MSLN in Patients With Relapsed and Refractory Epithelial Ovarian Cancer", "status": "TERMINATED", "last_update": "2022-08-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05372692", "title": "Study of LD013 in Subjects With Refractory or Relapsed Mesothelin -Positive Ovarian Cancer", "status": "COMPLETED", "last_update": "2023-07-17", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05451849", "title": "A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer", "status": "TERMINATED", "last_update": "2026-07-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05963100", "title": "Clinical Study of TCR-like CAR-T Cell Targeted MSLN in the Treatment of Ovarian Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-04-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06256055", "title": "Phase 1 Study of UCMYM802 Injection in Mesothelin-positive Advanced Malignant Solid Tumors", "status": "UNKNOWN", "last_update": "2024-07-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06523803", "title": "A Study of ZW171 in Participants With Advanced or Metastatic Mesothelin-expressing Cancers", "status": "TERMINATED", "last_update": "2025-10-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07420010", "title": "An Open-label, Single-arm Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile, and Preliminary Efficacy of KT032 Cell Injection in Patients With Mesothelin-positive Advanced Solid Tumors.", "status": "NOT_YET_RECRUITING", "last_update": "2026-02-19", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" } ], "cell_therapy": { "n": 15, "n_observational": 0, "n_active": 8, "n_withdrawn": 0, "trials": [ { "nct": "NCT05410717", "title": "CLDN6/GPC3/Mesothelin/AXL-CAR-NK Cell Therapy for Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2024-06-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06051695", "title": "A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression", "status": "RECRUITING", "last_update": "2026-06-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06885697", "title": "Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma", "status": "RECRUITING", "last_update": "2026-08-26", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07480954", "title": "Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FR\u03b1, MUC16)", "status": "RECRUITING", "last_update": "2026-03-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07523529", "title": "Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-04-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07589543", "title": "Dual-Target CAR-NK Cells in Recurrent or Refractory Epithelial Ovarian Cancer", "status": "RECRUITING", "last_update": "2026-05-15", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07617753", "title": "Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FR\u03b1, MUC16) pt2", "status": "RECRUITING", "last_update": "2026-06-01", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01583686", "title": "CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer", "status": "TERMINATED", "last_update": "2019-10-14", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02159716", "title": "CART-meso in Mesothelin Expressing Cancers", "status": "COMPLETED", "last_update": "2025-06-29", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02580747", "title": "Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART-meso", "status": "UNKNOWN", "last_update": "2015-10-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03054298", "title": "CAR T Cells in Mesothelin Expressing Cancers", "status": "COMPLETED", "last_update": "2025-04-29", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03692637", "title": "Study of Anti-Mesothelin Car NK Cells in Epithelial Ovarian Cancer", "status": "UNKNOWN", "last_update": "2019-01-31", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04503980", "title": "\u03b1PD1-MSLN-CAR T Cells for the Treatment of MSLN-positive Advanced Solid Tumors", "status": "UNKNOWN", "last_update": "2020-08-07", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04562298", "title": "A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of LCAR-M23, a CAR-T Cell Therapy Targeting MSLN in Patients With Relapsed and Refractory Epithelial Ovarian Cancer", "status": "TERMINATED", "last_update": "2022-08-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05963100", "title": "Clinical Study of TCR-like CAR-T Cell Targeted MSLN in the Treatment of Ovarian Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-04-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ] }, "synonyms_searched": [ "mesothelin", "MSLN", "anetumab" ] }, "NaPi2b": { "n": 8, "n_observational": 0, "n_active": 2, "n_withdrawn": 0, "trials": [ { "nct": "NCT06303505", "title": "FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC", "status": "RECRUITING", "last_update": "2026-09-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03319628", "title": "First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2023-11-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04396340", "title": "First-in-Human Study of XMT-1592 in Patients With Ovarian Cancer and NSCLC Likely to Express NaPi2b", "status": "TERMINATED", "last_update": "2024-03-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04461457", "title": "Targeted Radiation Therapy for Ovarian Cancer: Intraperitoneal Treatment With 211-astatine-MX35 F(ab')2", "status": "COMPLETED", "last_update": "2020-07-08", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04907968", "title": "Study of Upifitamab Rilsodotin in Combination With Carboplatin in Participants With High-grade Serous Ovarian Cancer", "status": "TERMINATED", "last_update": "2023-10-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05329545", "title": "Upifitamab Rilsodotin Maintenance in Platinum-Sensitive Recurrent Ovarian Cancer (UP-NEXT)", "status": "TERMINATED", "last_update": "2023-10-26", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06517433", "title": "First-in-Human Dose Escalation Study of XMT-1536 in Cancers Likely to Express NaPi2b", "status": "COMPLETED", "last_update": "2024-07-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06517485", "title": "First-in-Human Dose Expansion Study of XMT-1536 in Cancers Likely to Express NaPi2b", "status": "COMPLETED", "last_update": "2024-07-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ], "cell_therapy": { "n": 0, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [] }, "synonyms_searched": [ "NaPi2b", "SLC34A2", "upifitamab" ] }, "HER2": { "n": 111, "n_observational": 8, "n_active": 51, "n_withdrawn": 9, "trials": [ { "nct": "NCT04389632", "title": "A Study of Sigvotatug Vedotin in Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-07-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04585958", "title": "Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian Cancer", "status": "RECRUITING", "last_update": "2026-09-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05333328", "title": "OFS in Premenopausal Node+ Breast Cancer With Low Genomic Risk", "status": "RECRUITING", "last_update": "2025-05-22", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05417594", "title": "Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies", "status": "RECRUITING", "last_update": "2026-08-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05579366", "title": "Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)", "status": "RECRUITING", "last_update": "2026-08-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05735080", "title": "Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer", "status": "RECRUITING", "last_update": "2026-04-01", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05768139", "title": "First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-07-07", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05786716", "title": "DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With HER2 Amplification or Activating Mutations", "status": "RECRUITING", "last_update": "2025-12-02", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05824975", "title": "A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)", "status": "RECRUITING", "last_update": "2024-11-25", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05867251", "title": "Study of AVZO-021 in Patients With Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2025-11-19", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05879926", "title": "Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25", "status": "RECRUITING", "last_update": "2026-09-02", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05969041", "title": "Study of MT-302 in Adults With Advanced or Metastatic Epithelial Tumors", "status": "RECRUITING", "last_update": "2024-01-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06084481", "title": "Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400", "status": "RECRUITING", "last_update": "2026-08-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06293898", "title": "Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors", "status": "RECRUITING", "last_update": "2026-09-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06330064", "title": "A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)", "status": "RECRUITING", "last_update": "2026-08-05", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06420973", "title": "RC48 Treatment for Platinum Sensitive Recurrent Ovarian Cancer With HER2 Expression", "status": "RECRUITING", "last_update": "2024-05-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06660511", "title": "Exploratory Study on the Safety and Efficacy of Disitamab Vedotin in Combination with Anlotinib Hydrochloride for the Treatment of HER-2-expressing Recurrent Platinum-resistant Ovarian Cancer.", "status": "RECRUITING", "last_update": "2024-10-28", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06695845", "title": "A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors", "status": "RECRUITING", "last_update": "2026-07-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06760819", "title": "A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)", "status": "RECRUITING", "last_update": "2026-09-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06769425", "title": "HS-10502 Combination Treatment in Patients With Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2025-06-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06819007", "title": "Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)", "status": "RECRUITING", "last_update": "2026-07-02", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06993844", "title": "Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-06-23", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07109726", "title": "A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations", "status": "RECRUITING", "last_update": "2026-08-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07159451", "title": "A Short-term Preoperative, Evaluating Activity and Safety of Elacestrant Monotherapy as Compared to Elacestrant + Ovarian Function Suppression (LHRH Agonist) in Premenopausal Patients With Stage I-II ER+/HER2- Breast Cancer", "status": "RECRUITING", "last_update": "2025-12-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07311577", "title": "Disitamab Vedotin Combined With Platinum and Bevacizumab as First-Line and Maintenance Therapy for HER2-Expressing, HRD-Negative High-Risk Ovarian Cancer: A Multicenter, Non-Randomized, Single-Arm Phase II Clinical Study", "status": "RECRUITING", "last_update": "2025-12-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07334119", "title": "Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-304 in Adults With Advanced HER2-Expressing Solid Tumors", "status": "RECRUITING", "last_update": "2026-05-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07340164", "title": "Trastzumab Deruxtecan Versus SOC in Recurrent Ovarian That Progressed on Prior PARP Inhibitor Therapy", "status": "RECRUITING", "last_update": "2026-04-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07424547", "title": "Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors", "status": "RECRUITING", "last_update": "2026-04-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07523529", "title": "Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-04-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07524322", "title": "Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-07-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07612891", "title": "A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-6452 in Adult Patients With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Advanced/Metastatic Breast Cancer or Locally Advanced/Metastatic Solid Tumor", "status": "RECRUITING", "last_update": "2026-05-29", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00003002", "title": "HER-2/Neu Vaccine Plus GM-CSF in Treating Patients With Stage III or Stage IV Breast, Ovarian, or Non-small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2019-02-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00004074", "title": "Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu", "status": "COMPLETED", "last_update": "2013-02-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00005023", "title": "Vaccine Therapy Plus Sargramostim in Treating Patients With Stage III or Stage IV Cancer", "status": "COMPLETED", "last_update": "2017-11-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00005956", "title": "Biological Therapy in Treating Patients With Advanced Cancer", "status": "COMPLETED", "last_update": "2014-07-09", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00017537", "title": "Vaccine Therapy in Treating Patients With Metastatic or Recurrent Cancer", "status": "WITHDRAWN", "last_update": "2013-08-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00028535", "title": "Interleukin-12, Paclitaxel, and Trastuzumab in Treating Patients With Solid Tumors", "status": "COMPLETED", "last_update": "2013-06-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00031681", "title": "7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)", "status": "COMPLETED", "last_update": "2013-09-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00034281", "title": "Safety and Tolerability Study of TAK-165 in Subjects With Tumors Expressing HER2", "status": "COMPLETED", "last_update": "2012-02-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00058552", "title": "A Study to Evaluate the Effect of HER2 Activation on rhuMAb 2C4 (Pertuzumab) in Subjects With Advanced Ovarian Cancer", "status": "COMPLETED", "last_update": "2017-03-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00096993", "title": "A Study to Evaluate rhuMab 2C4 and Gemcitabine in Subjects With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer", "status": "COMPLETED", "last_update": "2015-06-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00189579", "title": "Addition of Herceptin to a Carboplatin-Paclitaxel Regimen in Patients With Ovarian Cancer", "status": "TERMINATED", "last_update": "2007-08-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00194714", "title": "Vaccine Therapy in Treating Patients With Stage IV HLA-A2 and HER2 Positive Breast or Ovarian Cancer Receiving Trastuzumab", "status": "COMPLETED", "last_update": "2024-06-06", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00228358", "title": "Cyclophosphamide or Denileukin Diftitox Followed By Expanding a Patient's Own T Cells in the Laboratory in Treating Patients With HER-2/Neu Overexpressing Metastatic Breast Cancer, Ovarian Cancer, or Non-Small Cell Lung Cancer Previously Treated With HER-2/Neu Vaccine", "status": "COMPLETED", "last_update": "2014-11-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00291473", "title": "Safety and Immunogenicity of CHP-HER2 and CHP-NY-ESO-1 Protein With OK-432 in Antigen-Expressing Cancers", "status": "COMPLETED", "last_update": "2009-03-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00363012", "title": "Immune Response in Patients Who Have Undergone Vaccine Therapy for Stage III or Stage IV Breast Cancer That Overexpresses HER2", "status": "COMPLETED", "last_update": "2017-04-05", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00373217", "title": "Vaccine Therapy, Paclitaxel, and Carboplatin in Treating Patients Who Are Undergoing Surgery for Stage III or Stage IV Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer", "status": "TERMINATED", "last_update": "2022-09-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00433407", "title": "T-Cell Response in Patients Receiving Trastuzumab and/or Chemotherapy for HER2-Positive Solid Tumors", "status": "COMPLETED", "last_update": "2012-10-04", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00436254", "title": "Vaccine Therapy With Sargramostim (GM-CSF) in Treating Patients With Her-2 Positive Stage III-IV Breast Cancer or Ovarian Cancer", "status": "COMPLETED", "last_update": "2025-04-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00447226", "title": "Randomized Discontinuation Study of Lapatinib Versus Placebo in Subjects With Documented Tumor Progression After Chemotherapy, or Where no Approved Therapy Exists", "status": "TERMINATED", "last_update": "2012-06-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01209195", "title": "A Study of MM-121 in Combination With Paclitaxel in Patients With Advanced Gynecologic and Breast Cancers", "status": "COMPLETED", "last_update": "2016-09-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01376505", "title": "Vaccine Therapy in Treating Patients With Metastatic Solid Tumors", "status": "COMPLETED", "last_update": "2023-09-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01384253", "title": "Safety Study of \u00b2\u00b9\u00b2Pb-TCMC-Trastuzumab Radio Immunotherapy", "status": "COMPLETED", "last_update": "2016-09-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01905592", "title": "A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients", "status": "TERMINATED", "last_update": "2022-11-15", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01928186", "title": "FLT PET in Measuring Treatment Response in Patients With Newly Diagnosed Estrogen Receptor-Positive, HER2-Negative Stage I-III Breast Cancer", "status": "COMPLETED", "last_update": "2018-05-15", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02025985", "title": "Study of KPT-330 (Selinexor) in Female Patients With Advanced Gynaecologic Malignancies", "status": "COMPLETED", "last_update": "2023-01-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02264678", "title": "Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02344550", "title": "Study of GnRH-A [Leuprorelin(Lorelin Depot] Plus Leterozole +/- Everolimus for Premenopausal Women With Metastatic Breast Cancer", "status": "COMPLETED", "last_update": "2020-07-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02418624", "title": "Phase I of Carboplatin-Olaparib Followed by Olaparib Monotherapy in Advanced Cancer", "status": "COMPLETED", "last_update": "2019-01-16", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02465060", "title": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02470559", "title": "Activated T-cell Therapy, Low-Dose Aldesleukin, and Sargramostim in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer That is Stage III-IV, Refractory, or Recurrent", "status": "WITHDRAWN", "last_update": "2016-02-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02713984", "title": "A Clinical Research of CAR T Cells Targeting HER2 Positive Cancer", "status": "WITHDRAWN", "last_update": "2020-03-19", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02892123", "title": "Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers", "status": "COMPLETED", "last_update": "2024-11-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02894398", "title": "Study in Women With Advanced Breast Cancer Receiving Palbociclib With AI or Fulvestrant", "status": "COMPLETED", "last_update": "2023-03-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02917005", "title": "PalbocIclib in PreMenopausal Women With ER Positive/HER-2 Negative MetAstatic Breast Cancer", "status": "UNKNOWN", "last_update": "2021-07-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03134638", "title": "A Study of SY-1365 in Adult Patients With Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2021-03-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03197584", "title": "QUILT-3.051: NANT Ovarian Cancer Vaccine: Combination Immunotherapy in Subjects With Epithelial Ovarian Cancer Who Have Progressed on or After Standard-of-care (SoC) Therapy", "status": "WITHDRAWN", "last_update": "2025-02-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03294694", "title": "Ribociclib + PDR001 in Breast Cancer and Ovarian Cancer", "status": "TERMINATED", "last_update": "2025-05-31", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03430518", "title": "Durvalumab and Eribulin in Her2-negative Metastatic Breast Cancer and Recurrent Ovarian Cancer", "status": "COMPLETED", "last_update": "2020-08-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03519178", "title": "A Study of PF-06873600 in People With Cancer", "status": "TERMINATED", "last_update": "2025-11-14", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03602079", "title": "Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene", "status": "COMPLETED", "last_update": "2023-08-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03628066", "title": "Biological and Clinical Effects of Palbociclib With Ovarian Suppression and Letrozole in the Neoadjuvant Treatment of Breast Cancer", "status": "COMPLETED", "last_update": "2022-04-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03746431", "title": "A Phase 1 Study of [225Ac]-FPI-1434 Injection", "status": "TERMINATED", "last_update": "2026-01-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03821233", "title": "A Dose Finding Study of ZW49 in Patients With HER2-Positive Cancers", "status": "COMPLETED", "last_update": "2025-01-29", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03970382", "title": "A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors", "status": "SUSPENDED", "last_update": "2022-08-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03979339", "title": "Feasibility of a New Technology for Isolating Circulating Tumour Cells", "status": "UNKNOWN", "last_update": "2021-10-13", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04025216", "title": "A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers", "status": "TERMINATED", "last_update": "2024-01-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04152499", "title": "Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04182516", "title": "Study of NMS-03305293 in Pts with Selected Advanced/Metastatic Solid Tumors", "status": "TERMINATED", "last_update": "2024-09-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04319757", "title": "ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors", "status": "COMPLETED", "last_update": "2024-12-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04421963", "title": "Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-12", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04464967", "title": "Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers", "status": "WITHDRAWN", "last_update": "2021-05-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04482309", "title": "A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04485013", "title": "TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04498520", "title": "Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer", "status": "WITHDRAWN", "last_update": "2021-05-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04511871", "title": "A Phase I Trial of CCT303-406 in Patients With Relapsed or Refractory HER2 Positive Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-10-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04553133", "title": "PF-07104091 as a Single Agent and in Combination Therapy", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04602117", "title": "ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer", "status": "WITHDRAWN", "last_update": "2023-11-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04639219", "title": "A Study of T-DXd for the Treatment of Solid Tumors Harboring HER2 Activating Mutations", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04644068", "title": "Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-19", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04660929", "title": "CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors", "status": "UNKNOWN", "last_update": "2024-12-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04665921", "title": "A Study of SGN-STNV in Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2025-02-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04828616", "title": "Study of DP303c Injection in Patients With Advanced Ovarian Cancer", "status": "UNKNOWN", "last_update": "2021-04-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04906395", "title": "Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-13", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04931342", "title": "A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05194072", "title": "A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2026-01-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05238831", "title": "SMMART Adaptive Clinical Treatment (ACT) Trial", "status": "WITHDRAWN", "last_update": "2024-01-23", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05238922", "title": "Study of INCB123667 in Subjects With Advanced Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05395052", "title": "FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2023-09-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05472532", "title": "Evaluation of an Automated System to Culture Metastatic Patient Circulating Tumor Cells in Embryonated Chicken Eggs (in Ovo Culture)", "status": "COMPLETED", "last_update": "2025-11-20", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05645536", "title": "Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study", "status": "ENROLLING_BY_INVITATION", "last_update": "2026-09-01", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05904730", "title": "Phase I Clinical Trials Investigating the Potential Efficacy of Axitinib in Patients With a BRCA 1/2 Mutations", "status": "COMPLETED", "last_update": "2024-12-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05905341", "title": "Study of PF-07224826, as a Single Agent or in Combination With Endocrine Therapy in Participants With Breast Cancer and Other Advanced Solid Tumors.", "status": "WITHDRAWN", "last_update": "2023-11-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06003231", "title": "A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06243185", "title": "Dalpiciclib Combined With Letrozole in HR+/HER2 - Gynecologic Solid Tumors", "status": "UNKNOWN", "last_update": "2024-02-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06257264", "title": "A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06574763", "title": "Neoadjuvant RC48 Plus Carboplatin for HER2-expressing Advanced Ovarian Cancer", "status": "UNKNOWN", "last_update": "2024-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06714617", "title": "Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-11-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06990503", "title": "SHR - A1811 Versus Chemotherapy for Platinum-resistant Recurrent Epithelial Ovarian Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2025-05-25", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07545460", "title": "A Study Comparing BL-M07D1 With Physician's Choice of Chemotherapy in Patients With HER2-Expressing Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-06-29", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07631871", "title": "An Exploratory Study of Zanidatamab in HER2-positive Advanced Tumor After at Least One Line of Standard Therapy", "status": "NOT_YET_RECRUITING", "last_update": "2026-06-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ], "cell_therapy": { "n": 6, "n_observational": 0, "n_active": 1, "n_withdrawn": 2, "trials": [ { "nct": "NCT07523529", "title": "Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-04-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00228358", "title": "Cyclophosphamide or Denileukin Diftitox Followed By Expanding a Patient's Own T Cells in the Laboratory in Treating Patients With HER-2/Neu Overexpressing Metastatic Breast Cancer, Ovarian Cancer, or Non-Small Cell Lung Cancer Previously Treated With HER-2/Neu Vaccine", "status": "COMPLETED", "last_update": "2014-11-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02470559", "title": "Activated T-cell Therapy, Low-Dose Aldesleukin, and Sargramostim in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer That is Stage III-IV, Refractory, or Recurrent", "status": "WITHDRAWN", "last_update": "2016-02-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02713984", "title": "A Clinical Research of CAR T Cells Targeting HER2 Positive Cancer", "status": "WITHDRAWN", "last_update": "2020-03-19", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03970382", "title": "A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors", "status": "SUSPENDED", "last_update": "2022-08-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04025216", "title": "A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers", "status": "TERMINATED", "last_update": "2024-01-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "synonyms_searched": [ "HER2", "ERBB2", "trastuzumab deruxtecan" ] }, "CLDN6": { "n": 12, "n_observational": 0, "n_active": 9, "n_withdrawn": 1, "trials": [ { "nct": "NCT05103683", "title": "First in Human Study of TORL-1-23 in Participants With Advanced Cancer", "status": "RECRUITING", "last_update": "2026-02-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05410717", "title": "CLDN6/GPC3/Mesothelin/AXL-CAR-NK Cell Therapy for Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2024-06-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06276491", "title": "Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-08-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06515613", "title": "A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-09-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06690775", "title": "CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.", "status": "RECRUITING", "last_update": "2025-12-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07304128", "title": "A Study of PLB-002 in Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-03-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07593092", "title": "Phase 1, Safety and Tolerability Study of XmAb541 and XmAb808 in Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-08-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02054351", "title": "Phase 1 Trial of IMAB027 in Patients With Recurrent Advanced Ovarian Cancer (OVAR)", "status": "COMPLETED", "last_update": "2024-11-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04503278", "title": "A Clinical Study of the Safety and Effectiveness of an Investigational Cell Therapy Given With and Without an Investigational RNA-based Vaccine in Patients With Organ Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05317078", "title": "A Phase 1 Safety, Tolerability, and Pharmacokinetics Study of AMG 794 With Claudin 6-positive Non-small Cell Lung Cancer, Epithelial Ovarian Cancer, and Other Malignant Solid Tumor Indications", "status": "TERMINATED", "last_update": "2025-10-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06681870", "title": "A Study of ASP1893 in Adults With Advanced CLDN6-positive Solid Tumors", "status": "WITHDRAWN", "last_update": "2025-01-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07453394", "title": "QLS5132 Combination Therapy in Advanced Solid Tumors", "status": "NOT_YET_RECRUITING", "last_update": "2026-03-06", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ], "cell_therapy": { "n": 2, "n_observational": 0, "n_active": 2, "n_withdrawn": 0, "trials": [ { "nct": "NCT05410717", "title": "CLDN6/GPC3/Mesothelin/AXL-CAR-NK Cell Therapy for Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2024-06-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04503278", "title": "A Clinical Study of the Safety and Effectiveness of an Investigational Cell Therapy Given With and Without an Investigational RNA-based Vaccine in Patients With Organ Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "synonyms_searched": [ "CLDN6", "claudin 6", "claudin-6" ] }, "B7-H4": { "n": 4, "n_observational": 0, "n_active": 2, "n_withdrawn": 0, "trials": [ { "nct": "NCT06014190", "title": "HS-20089 in Patients With Ovarian Cancer and Endometrial Cancer", "status": "RECRUITING", "last_update": "2024-08-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06774963", "title": "A Phase 1 Study of LNCB74 in Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-08-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03514121", "title": "FPA150 in Patients With Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2024-11-22", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05067972", "title": "A Study of PF-07260437 in Advanced or Metastatic Solid Tumors", "status": "TERMINATED", "last_update": "2025-05-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ], "cell_therapy": { "n": 0, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [] }, "synonyms_searched": [ "B7-H4", "VTCN1" ] }, "TROP2": { "n": 11, "n_observational": 0, "n_active": 9, "n_withdrawn": 0, "trials": [ { "nct": "NCT05489211", "title": "Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)", "status": "RECRUITING", "last_update": "2026-08-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05867251", "title": "Study of AVZO-021 in Patients With Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2025-11-19", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05941507", "title": "A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2025-09-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05969041", "title": "Study of MT-302 in Adults With Advanced or Metastatic Epithelial Tumors", "status": "RECRUITING", "last_update": "2024-01-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06851663", "title": "Trop2-targeted immunoPET Imaging of Solid Tumors", "status": "RECRUITING", "last_update": "2026-05-29", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06953089", "title": "DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors", "status": "RECRUITING", "last_update": "2026-05-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04152499", "title": "Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05922930", "title": "Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells Delivered Intraperitoneally for the Management of Platinum Resistant Ovarian Cancer, Mesonephric-like Adenocarcinoma, and Pancreatic Cancer", "status": "SUSPENDED", "last_update": "2026-07-30", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06028932", "title": "A Study of Sacituzumab Govitecan (IMMU-132) in Platinum-resistant Ovarian Cancer Patients", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06865677", "title": "Sacituzumab Govitecan for Relapsed Ovarian, Endometrial, and Cervical Carcinomas", "status": "TERMINATED", "last_update": "2026-01-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07674615", "title": "IMMU-132 in TROP-2 Overexpressed Advanced and Relapsed Ovarian Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-06-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ], "cell_therapy": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT05922930", "title": "Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells Delivered Intraperitoneally for the Management of Platinum Resistant Ovarian Cancer, Mesonephric-like Adenocarcinoma, and Pancreatic Cancer", "status": "SUSPENDED", "last_update": "2026-07-30", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ] }, "synonyms_searched": [ "TROP2", "TROP-2", "TACSTD2" ] }, "PD-L1": { "n": 105, "n_observational": 2, "n_active": 33, "n_withdrawn": 4, "trials": [ { "nct": "NCT04585750", "title": "The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)", "status": "RECRUITING", "last_update": "2026-08-10", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04644289", "title": "WoO: Window of Opportunity Trial of Olaparib and Durvalumab in Histologically Proven EOC", "status": "RECRUITING", "last_update": "2025-10-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04918186", "title": "Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer", "status": "RECRUITING", "last_update": "2026-07-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04954599", "title": "Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI", "status": "RECRUITING", "last_update": "2025-10-07", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05000294", "title": "Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types", "status": "RECRUITING", "last_update": "2026-07-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05092373", "title": "Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax", "status": "RECRUITING", "last_update": "2026-07-16", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05187338", "title": "Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2024-06-25", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05410717", "title": "CLDN6/GPC3/Mesothelin/AXL-CAR-NK Cell Therapy for Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2024-06-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05538091", "title": "Vismodegib Combined With Atezolizumab in Platinum Resistant Ovarian, Fallopian Tube, and Primary Peritoneal Cancer", "status": "RECRUITING", "last_update": "2026-06-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06769152", "title": "A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX43 (Anti-PD-L1 ADC) in Patients With Advanced Gynecological Malignant Tumors", "status": "RECRUITING", "last_update": "2026-04-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06953089", "title": "DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors", "status": "RECRUITING", "last_update": "2026-05-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07523529", "title": "Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-04-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01772004", "title": "Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)", "status": "COMPLETED", "last_update": "2021-12-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01975831", "title": "A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab", "status": "COMPLETED", "last_update": "2022-10-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02264678", "title": "Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02431559", "title": "Phase 1/2 Study of Motolimod, Doxorubicin, and Durvalumab in Recurrent, Platinum-Resistant Ovarian Cancer", "status": "COMPLETED", "last_update": "2022-10-10", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02484404", "title": "Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can...", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-17", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02499952", "title": "Pembrolizumab in Subjects With Incurable Platinum-Refractory Germ Cell Tumors", "status": "TERMINATED", "last_update": "2022-07-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02554812", "title": "A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley)", "status": "TERMINATED", "last_update": "2024-07-30", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02644369", "title": "Study of the Effects of Pembrolizumab in Patients With Advanced Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02658214", "title": "Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2020-08-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02659384", "title": "Anti-programmed Cell Death-1 Ligand 1 (aPDL-1) Antibody Atezolizumab, Bevacizumab and Acetylsalicylic Acid in Recurrent Platinum Resistant Ovarian Cancer", "status": "COMPLETED", "last_update": "2023-03-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02669914", "title": "MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors", "status": "TERMINATED", "last_update": "2018-11-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02674061", "title": "Efficacy and Safety Study of Pembrolizumab (MK-3475) in Participants With Advanced Recurrent Ovarian Cancer (MK-3475-100/KEYNOTE-100)", "status": "COMPLETED", "last_update": "2022-03-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02725489", "title": "Pilot Study of Durvalumab and Vigil in Advanced Women's Cancers", "status": "COMPLETED", "last_update": "2021-01-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02726997", "title": "Matched Paired Pharmacodynamics and Feasibility Study of Durvalumab in Combination With Chemotherapy in Frontline Ovarian Cancer (N-Dur)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02734004", "title": "A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors.", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-14", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02764333", "title": "TPIV200/huFR-1 (A Multi-Epitope Anti-Folate Receptor Vaccine) Plus Anti-PD-L1 MEDI4736 (Durvalumab) in Patients With Platinum Resistant Ovarian Cancer", "status": "COMPLETED", "last_update": "2021-11-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02811497", "title": "Study of Azacitidine and Durvalumab in Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2021-04-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02839707", "title": "Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02876510", "title": "ACTolog in Patients With Solid Cancers", "status": "COMPLETED", "last_update": "2025-02-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02891824", "title": "ATALANTE: Atezolizumab vs Placebo Phase III Study in Late Relapse Ovarian Cancer Treated With Chemotherapy+Bevacizumab", "status": "COMPLETED", "last_update": "2025-02-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02914470", "title": "Carboplatin-cyclophosphamide Combined With Atezolizumab", "status": "COMPLETED", "last_update": "2021-10-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02915523", "title": "Study of Avelumab With or Without Entinostat in Participants With Advanced Epithelial Ovarian Cancer", "status": "COMPLETED", "last_update": "2024-01-10", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02953457", "title": "Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation", "status": "COMPLETED", "last_update": "2024-11-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02963831", "title": "A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies", "status": "COMPLETED", "last_update": "2022-12-22", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03026062", "title": "Durvalumab and Tremelimumab in Treating Participants With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer", "status": "COMPLETED", "last_update": "2026-08-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03038100", "title": "A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer", "status": "COMPLETED", "last_update": "2023-02-17", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03073525", "title": "A Trial of Atezolizumab and Vigil in Patients With Advanced Gynecological Cancers", "status": "COMPLETED", "last_update": "2023-04-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03085225", "title": "Trabectedin Combined With Durvalumab in Patients With Advanced Pretreated Soft-tissue Sarcomas and Ovarian Carcinomas.", "status": "COMPLETED", "last_update": "2025-09-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03126110", "title": "Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies", "status": "COMPLETED", "last_update": "2025-08-14", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03170960", "title": "Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-08-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03197584", "title": "QUILT-3.051: NANT Ovarian Cancer Vaccine: Combination Immunotherapy in Subjects With Epithelial Ovarian Cancer Who Have Progressed on or After Standard-of-care (SoC) Therapy", "status": "WITHDRAWN", "last_update": "2025-02-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03206047", "title": "Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer", "status": "COMPLETED", "last_update": "2025-03-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03241173", "title": "A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies", "status": "COMPLETED", "last_update": "2022-09-27", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03249142", "title": "Immunotherapy With Neo-adjuvant Chemotherapy for OVarian Cancer", "status": "COMPLETED", "last_update": "2025-12-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03267589", "title": "Trial in Patients With Relapsed Ovarian Cancer", "status": "COMPLETED", "last_update": "2025-07-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03277482", "title": "Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer", "status": "TERMINATED", "last_update": "2025-05-31", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03283943", "title": "PDL-1 Inhibition and Focal Sensitizing Radiotherapy in Recurrent Ovarian/Primary Peritoneal/Fallopian Tube Cancers.", "status": "UNKNOWN", "last_update": "2018-07-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03292172", "title": "A Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (PD-L1 Antibody) in Participants With Advanced Ovarian Cancer or Triple Negative Breast Cancer", "status": "TERMINATED", "last_update": "2020-11-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03312114", "title": "Anti-PD-L1 and SAbR for Ovarian Cancer", "status": "TERMINATED", "last_update": "2020-11-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03323398", "title": "Dose Escalation and Efficacy Study of mRNA-2416 for Intratumoral Injection Alone and in Combination With Durvalumab for Participants With Advanced Malignancies", "status": "TERMINATED", "last_update": "2024-07-31", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03330405", "title": "Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors", "status": "TERMINATED", "last_update": "2023-10-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03353831", "title": "Atezolizumab With Bevacizumab and Chemotherapy vs Bevacizumab and Chemotherapy in Early Relapse Ovarian Cancer", "status": "COMPLETED", "last_update": "2025-04-06", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03363867", "title": "BEACON - ABC in Recurrent Platinum Resistant HGSOC", "status": "UNKNOWN", "last_update": "2023-08-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03365791", "title": "PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies", "status": "COMPLETED", "last_update": "2022-05-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03394885", "title": "Atezolizumab With Neoadjuvant Chemotherapy for Patients With Newly-Diagnosed Advanced-Stage Ovarian Cancer", "status": "COMPLETED", "last_update": "2021-08-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03410784", "title": "Pembrolizumab With Chemotherapy in Front Line Advanced Ovarian, Primary Peritoneal and Fallopian Tube Cancer", "status": "UNKNOWN", "last_update": "2023-03-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03430518", "title": "Durvalumab and Eribulin in Her2-negative Metastatic Breast Cancer and Recurrent Ovarian Cancer", "status": "COMPLETED", "last_update": "2020-08-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03549000", "title": "A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies.", "status": "TERMINATED", "last_update": "2024-12-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03574779", "title": "A Study to Evaluate the Efficacy and Safety of Novel Treatment Combinations in Participants With Ovarian Cancer", "status": "COMPLETED", "last_update": "2025-07-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03598270", "title": "Platinum-based Chemotherapy With Atezolizumab and Niraparib in Patients With Recurrent Ovarian Cancer", "status": "COMPLETED", "last_update": "2024-08-30", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03660826", "title": "Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03695380", "title": "A Clinical Study of Cobimetinib Administered in Combination With Niraparib, With or Without Atezolizumab to Patients With Advanced Platinum-sensitive Ovarian Cancer", "status": "COMPLETED", "last_update": "2023-08-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03699449", "title": "An uMbrella Study of BIomarker-driven Targeted Therapy In Patients With Platinum-resistant Recurrent OvariaN Cancer(AMBITION)", "status": "UNKNOWN", "last_update": "2021-04-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03737643", "title": "Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-07", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03740165", "title": "Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036)", "status": "COMPLETED", "last_update": "2026-08-19", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03797326", "title": "Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)", "status": "COMPLETED", "last_update": "2026-05-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03821935", "title": "Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-05-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03861793", "title": "A Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine ALKS 4230 (Nemvaleukin Alfa) as a Single Agent and in Combination With Anti-PD-1 Antibody (Pembrolizumab) in Subjects With Select Advanced or Metastatic Solid Tumors (ARTISTRY-2)", "status": "COMPLETED", "last_update": "2024-03-05", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03899610", "title": "A Phase II Study of Neoadjuvant Chemotherapy Plus Durvalumab (MEDI4736) and Tremelimumab in Advanced-stage Ovarian Cancer (TRU-D)", "status": "UNKNOWN", "last_update": "2020-09-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03955471", "title": "Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (TSR-042) in Participants With Platinum Resistant Ovarian Cancer", "status": "TERMINATED", "last_update": "2022-09-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03983954", "title": "Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer.", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-11-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04015739", "title": "Tri Association in Patient With Advanced Epithelial Ovarian Cancer in Relapse", "status": "UNKNOWN", "last_update": "2022-08-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04019288", "title": "AVB-S6-500 and Durvalumab in Treating Patients With Platinum-Resistant or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer", "status": "TERMINATED", "last_update": "2025-06-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04042116", "title": "A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor", "status": "SUSPENDED", "last_update": "2022-12-20", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04065269", "title": "ATr Inhibitor in Combination With Olaparib/Durvalumab (MEDI4736) in Gynaecological Cancers With ARId1A Loss or no Loss", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04068974", "title": "Camrelizumab /Apatinib for Recurrent Platinum-resistant Ovarian Cancer", "status": "UNKNOWN", "last_update": "2021-03-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04116320", "title": "Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2025-07-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04244552", "title": "A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies", "status": "TERMINATED", "last_update": "2023-12-29", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04260802", "title": "A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers", "status": "TERMINATED", "last_update": "2026-01-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04442126", "title": "A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2025-05-23", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04510584", "title": "Maintenance Treatment With Bevacizumab and Atezolizumab for Ovarian Cancer", "status": "WITHDRAWN", "last_update": "2023-06-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04739800", "title": "Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04742075", "title": "Olaparib, Durvalumab and UV1 in Relapsed Ovarian Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04881045", "title": "Study to Test the Safety and Tolerability of PF-07257876 in Participants With Selected Advanced Tumors.", "status": "COMPLETED", "last_update": "2026-06-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04931342", "title": "A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05001347", "title": "A Clinical Study of TJ004309 With Atezolizumab (TECENTRIQ\u00ae) in Patients With Ovarian Cancer and Selected Solid Tumors", "status": "COMPLETED", "last_update": "2025-12-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05007106", "title": "MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)", "status": "COMPLETED", "last_update": "2025-08-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05061537", "title": "Study of PF-07263689 in Participants With Selected Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2024-04-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05065021", "title": "Using Genetic Profile to Determine the Treatment for Patients With Ovarian Cancer Who Previously Received a PARP-inhibitor", "status": "UNKNOWN", "last_update": "2024-01-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05116189", "title": "Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65).", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-09", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05145569", "title": "Antitumor Activity of Neoadjuvant Chemotherapy with or Without HCW9218 in Metastatic Advanced Stage Ovarian Cancer", "status": "WITHDRAWN", "last_update": "2025-01-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05200559", "title": "T-regulatory Cell Depletion With E7777 Combined With Pembrolizumab in Recurrent or Metastatic Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-29", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05238831", "title": "SMMART Adaptive Clinical Treatment (ACT) Trial", "status": "WITHDRAWN", "last_update": "2024-01-23", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05368207", "title": "Pembrolizumab in Small Cell Carcinoma of Ovary - Hypercalcemic Type Patient", "status": "COMPLETED", "last_update": "2026-06-23", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05395052", "title": "FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2023-09-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05756907", "title": "Combination of SON-1010 (IL12-FHAB) and Atezolizumab in Patients With Platinum-resistant Ovarian Cancer", "status": "TERMINATED", "last_update": "2026-02-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05787587", "title": "A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05949632", "title": "A Study of INCB099280 in Combination With Axitinib in Adults With Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2026-06-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06285097", "title": "A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2025-09-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06546553", "title": "A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines.", "status": "TERMINATED", "last_update": "2026-02-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06600841", "title": "Adebrelimab Combined with Non-platinum Chemotherapy and Fuzuloparib in Recurrent Platinum-resistant Ovarian Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2024-09-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06650709", "title": "NEoadjuvant Olaparib Combination OvArian Cancer Targeted Study", "status": "NOT_YET_RECRUITING", "last_update": "2024-10-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06724263", "title": "A Multicenter, Open-label Phase IIa Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Malignant Solid Tumors", "status": "NOT_YET_RECRUITING", "last_update": "2024-12-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ], "cell_therapy": { "n": 2, "n_observational": 0, "n_active": 2, "n_withdrawn": 0, "trials": [ { "nct": "NCT05410717", "title": "CLDN6/GPC3/Mesothelin/AXL-CAR-NK Cell Therapy for Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2024-06-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07523529", "title": "Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-04-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ] }, "synonyms_searched": [ "PD-L1", "atezolizumab", "durvalumab" ] }, "MUC1": { "n": 16, "n_observational": 1, "n_active": 5, "n_withdrawn": 1, "trials": [ { "nct": "NCT06483048", "title": "MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer", "status": "RECRUITING", "last_update": "2026-03-16", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07523529", "title": "Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-04-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07589543", "title": "Dual-Target CAR-NK Cells in Recurrent or Refractory Epithelial Ovarian Cancer", "status": "RECRUITING", "last_update": "2026-05-15", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00006041", "title": "Vaccine Therapy in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal Cancer", "status": "COMPLETED", "last_update": "2013-06-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00088413", "title": "PANVAC-V and PANVAC-F Vaccines Plus Sargramostim to Treat Advanced Cancer", "status": "COMPLETED", "last_update": "2019-04-16", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00703105", "title": "Ovarian Dendritic Cell Vaccine Trial", "status": "UNKNOWN", "last_update": "2021-04-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01068509", "title": "Ovarian Cancer Vaccine for Patients in Remission", "status": "COMPLETED", "last_update": "2017-05-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01223235", "title": "Polyvalent Vaccine-KLH Conjugate + Opt-821 Given in Combination With Bevacizumab", "status": "COMPLETED", "last_update": "2018-06-12", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01248273", "title": "Unimolecular Pentavalent (Globo-H-GM2-sTn-TF-Tn) Immunization of Patients With Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer in First Remission", "status": "COMPLETED", "last_update": "2017-03-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01521143", "title": "Cvac as Maintenance Treatment in Patients With Epithelial Ovarian Cancer in Complete Remission Following First-line Chemotherapy or Second-line Treatment", "status": "TERMINATED", "last_update": "2016-12-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01617629", "title": "Ovarian Cancer Vaccine for Patients Who Have Progressed During the CAN-003 Study", "status": "COMPLETED", "last_update": "2017-12-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02270372", "title": "Study of ONT-10 and Varlilumab to Treat Advanced Ovarian or Breast Cancer", "status": "COMPLETED", "last_update": "2018-05-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03197584", "title": "QUILT-3.051: NANT Ovarian Cancer Vaccine: Combination Immunotherapy in Subjects With Epithelial Ovarian Cancer Who Have Progressed on or After Standard-of-care (SoC) Therapy", "status": "WITHDRAWN", "last_update": "2025-02-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03652077", "title": "A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies", "status": "COMPLETED", "last_update": "2021-11-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05239143", "title": "P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07670312", "title": "Evaluation of XYA02 in Patients With Advanced Solid Tumors", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ], "cell_therapy": { "n": 4, "n_observational": 0, "n_active": 4, "n_withdrawn": 0, "trials": [ { "nct": "NCT06483048", "title": "MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer", "status": "RECRUITING", "last_update": "2026-03-16", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07523529", "title": "Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-04-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07589543", "title": "Dual-Target CAR-NK Cells in Recurrent or Refractory Epithelial Ovarian Cancer", "status": "RECRUITING", "last_update": "2026-05-15", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05239143", "title": "P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "synonyms_searched": [ "MUC1", "mucin-1" ] } }, "by_drug": { "ABAGOVOMAB": { "n": 3, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT00058435", "title": "Monoclonal Antibody Vaccine Therapy in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer", "status": "COMPLETED", "last_update": "2013-06-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00103545", "title": "Use of ACA 125 in Patients With Ovarian Cancer: Safety and Immune Response", "status": "COMPLETED", "last_update": "2006-10-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00418574", "title": "Efficacy Multicentre Trial of ImmunoTherapy Vaccination With Abagovomab to Treat Ovarian Cancer Patients", "status": "TERMINATED", "last_update": "2011-11-24", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" } ] }, "ALPELISIB": { "n": 7, "n_observational": 0, "n_active": 3, "n_withdrawn": 1, "trials": [ { "nct": "NCT05564377", "title": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial", "status": "RECRUITING", "last_update": "2026-09-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05768139", "title": "First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-07-07", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06993844", "title": "Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-06-23", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01623349", "title": "Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer", "status": "COMPLETED", "last_update": "2021-02-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01708161", "title": "A Phase Ib/II Study of the Combination of BYL719 Plus AMG 479 in Adult Patients With Selected Solid Tumors", "status": "TERMINATED", "last_update": "2018-09-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04729387", "title": "Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected", "status": "TERMINATED", "last_update": "2026-06-04", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05238831", "title": "SMMART Adaptive Clinical Treatment (ACT) Trial", "status": "WITHDRAWN", "last_update": "2024-01-23", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" } ] }, "AMATUXIMAB": { "n": 3, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT00325494", "title": "A Study of MORAb-009 in Subjects With Pancreatic Cancer, Mesothelioma, or Certain Types of Ovarian or Lung Cancer", "status": "COMPLETED", "last_update": "2014-07-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01413451", "title": "Amatuximab for High Mesothelin Cancers", "status": "TERMINATED", "last_update": "2019-12-17", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01521325", "title": "A Single-Dose Pilot Study of Radiolabeled Amatuximab (MORAb-009) in Mesothelin Over Expressing Cancers", "status": "COMPLETED", "last_update": "2016-09-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "ANETUMAB RAVTANSINE": { "n": 3, "n_observational": 0, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT02485119", "title": "Phase I Dose Escalation Study of BAY94-9343 Given by Intravenous Infusion Every 3 Weeks in Japanese Subjects With Advanced Malignancies", "status": "COMPLETED", "last_update": "2018-06-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02751918", "title": "Phase Ib Study of Anetumab Ravtansine in Combination With Pegylated Liposomal Doxorubicin in Patients With Recurrent Mesothelin-expressing Platinum-resistant Cancer", "status": "COMPLETED", "last_update": "2019-11-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03587311", "title": "Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "BUPARLISIB": { "n": 5, "n_observational": 0, "n_active": 0, "n_withdrawn": 1, "trials": [ { "nct": "NCT01068483", "title": "Safety of BKM120 Monotherapy in Advanced Solid Tumor Patients", "status": "COMPLETED", "last_update": "2020-12-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01363232", "title": "Safety, Pharmacokinetics and Pharmacodynamics of BKM120 Plus MEK162 in Selected Advanced Solid Tumor Patients", "status": "COMPLETED", "last_update": "2020-10-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01623349", "title": "Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer", "status": "COMPLETED", "last_update": "2021-02-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01833169", "title": "BKM120 for Patients With PI3K-activated Tumors", "status": "COMPLETED", "last_update": "2018-10-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02117817", "title": "Phase I BKM120/Abraxane in Solid Tumors, Expansion Phase Recurrent Endometrial or Ovarian Cancer", "status": "WITHDRAWN", "last_update": "2022-07-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "CONTUSUGENE LADENOVEC": { "n": 4, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT00002960", "title": "SCH-58500 in Treating Patients With Primary Ovarian, Fallopian Tube, or Peritoneal Cancer (C95084)", "status": "COMPLETED", "last_update": "2016-02-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00003450", "title": "Gene Therapy in Treating Patients With Advanced Recurrent or Persistent Ovarian Cancer or Primary Peritoneal Cancer", "status": "COMPLETED", "last_update": "2021-02-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00003588", "title": "Gene Therapy in Treating Patients With Ovarian Cancer", "status": "COMPLETED", "last_update": "2013-02-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00003880", "title": "Paclitaxel Plus Carboplatin With or Without SCH-58500 in Treating Patients With Newly Diagnosed Stage III Ovarian or Stage III Primary Peritoneal Cancer", "status": "TERMINATED", "last_update": "2015-04-16", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" } ] }, "COPANLISIB": { "n": 5, "n_observational": 0, "n_active": 1, "n_withdrawn": 1, "trials": [ { "nct": "NCT02465060", "title": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02728258", "title": "Copanlisib in Treating Patients With Persistent or Recurrent Endometrial Cancer", "status": "COMPLETED", "last_update": "2022-02-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03586661", "title": "Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer", "status": "COMPLETED", "last_update": "2026-07-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05082025", "title": "Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN Alterations", "status": "TERMINATED", "last_update": "2026-01-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05295589", "title": "Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor Therapy", "status": "WITHDRAWN", "last_update": "2023-09-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "EPRENETAPOPT": { "n": 2, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT02098343", "title": "p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246", "status": "COMPLETED", "last_update": "2025-03-17", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03268382", "title": "p53 Activation in Platinum-Resistant High Grade Serous Ovarian Cancer, a Study of PLD With APR-246", "status": "COMPLETED", "last_update": "2025-03-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "FARLETUZUMAB": { "n": 10, "n_observational": 0, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT04300556", "title": "A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FR\u03b1)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types", "status": "RECRUITING", "last_update": "2026-06-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00318370", "title": "Effectiveness of MORAb-003 in Women With Ovarian Cancer Who Have Relapsed After Platinum-Based Chemotherapy", "status": "COMPLETED", "last_update": "2015-09-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00428766", "title": "Safety, Tolerability and Pharmacokinetics of MORAb-003 in Subjects With Advanced Ovarian Cancer", "status": "COMPLETED", "last_update": "2013-11-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00738699", "title": "An Efficacy and Safety Study of MORAb-003 in Platinum-Resistant or Refractory Relapsed Ovarian Cancer", "status": "TERMINATED", "last_update": "2017-03-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00849667", "title": "Efficacy and Safety of Farletuzumab (MORAb-003) in Combination With Carboplatin and Taxane in Participants With Platinum-sensitive Ovarian Cancer in First Relapse", "status": "TERMINATED", "last_update": "2022-12-30", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01004380", "title": "Safety Study of Farletuzumab, Carboplatin and Pegylated Liposomal Doxorubicin (PLD) to Treat Platinum-sensitive Ovarian Cancer", "status": "COMPLETED", "last_update": "2014-07-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01018563", "title": "An Open Label Extension Study of the Efficacy of MORAb-003", "status": "TERMINATED", "last_update": "2021-12-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02289950", "title": "A Study to Assess the Efficacy and Safety of Farletuzumab (MORAb 003) in Combination With Carboplatin Plus Paclitaxel or Carboplatin Plus Pegylated Liposomal Doxorubicin (PLD) in Participants With Low CA125 Platinum-sensitive Ovarian Cancer", "status": "COMPLETED", "last_update": "2021-09-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03386942", "title": "A Study of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin) in Participants With Solid Tumors", "status": "COMPLETED", "last_update": "2022-11-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05613088", "title": "A Study of MORAb-202 Versus Investigator's Choice Chemotherapy in Female Participants With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer", "status": "COMPLETED", "last_update": "2026-04-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "GEDATOLISIB": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT02069158", "title": "Dose Finding Study Of PF-05212384 With Paclitaxel And Carboplatin In Patients With Advanced Solid Tumor", "status": "COMPLETED", "last_update": "2019-05-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "INAVOLISIB": { "n": 2, "n_observational": 0, "n_active": 2, "n_withdrawn": 0, "trials": [ { "nct": "NCT05768139", "title": "First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-07-07", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04931342", "title": "A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "MIRVETUXIMAB": { "n": 24, "n_observational": 2, "n_active": 14, "n_withdrawn": 0, "trials": [ { "nct": "NCT04606914", "title": "Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer", "status": "RECRUITING", "last_update": "2026-07-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05887609", "title": "An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib", "status": "RECRUITING", "last_update": "2026-07-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06682988", "title": "A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine", "status": "RECRUITING", "last_update": "2026-05-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06890338", "title": "A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FR\u03b1)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.", "status": "RECRUITING", "last_update": "2026-09-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07059845", "title": "A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer", "status": "RECRUITING", "last_update": "2026-08-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07213804", "title": "A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer", "status": "RECRUITING", "last_update": "2026-09-08", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07218809", "title": "AZD5335 vs. Mirvetuximab Soravtansine in FR\u03b1-high and AZD5335 vs. Chemotherapy in FR\u03b1-low Platinum-resistant Ovarian Cancer", "status": "RECRUITING", "last_update": "2026-07-21", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01609556", "title": "First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Mirvetuximab Soravtansine in Adults With Ovarian Cancer and Other Folate Receptor 1 (FOLR1)-Positive Solid Tumors", "status": "COMPLETED", "last_update": "2021-02-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02606305", "title": "Study of Mirvetuximab Soravtansine in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin in Participants With Folate Receptor Alpha (FR\u03b1) Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal, or Fallopian Tube Cancer", "status": "COMPLETED", "last_update": "2024-06-14", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02631876", "title": "A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer", "status": "COMPLETED", "last_update": "2020-10-14", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02996825", "title": "Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients With FRalpha-Positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial, or Triple Negative Breast Cancer", "status": "COMPLETED", "last_update": "2024-04-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03552471", "title": "Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer", "status": "COMPLETED", "last_update": "2025-02-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04209855", "title": "A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FR\u03b1) Expression", "status": "COMPLETED", "last_update": "2025-08-27", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04274426", "title": "Mirvetuximab Soravtansine (IMGN853), in Folate Receptor Alpha (FR\u03b1) High Recurrent Ovarian Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04296890", "title": "A Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression", "status": "COMPLETED", "last_update": "2024-08-07", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05041257", "title": "Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Peritoneal, and Fallopian Tube Cancers", "status": "COMPLETED", "last_update": "2026-01-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05445778", "title": "Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-02", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05456685", "title": "Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FR\u03b1) Expressing, Platinum-sensitive Epithelial Ovarian Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-10-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05483933", "title": "Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian Cancers", "status": "COMPLETED", "last_update": "2025-12-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05622890", "title": "A Single-arm Clinical Trial of IMGN853 in Chinese Adult Patients With Platinum-resistant, Epithelial Ovarian Cancer", "status": "UNKNOWN", "last_update": "2022-11-21", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06365853", "title": "A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06390995", "title": "A Study of TAK-853 in Adult Participants With Folate Receptor Alpha-Positive Advanced Ovarian Cancer And Other Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-16", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07741630", "title": "Mirvetuximab Soravtansine Combined With Suvemcitug in Platinum-Resistant Recurrent Ovarian Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07790939", "title": "89Zr-DFO-Mirvetuximab PET/CT Imaging for Companion Diagnosis and Response Evaluation in Ovarian Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-27", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" } ] }, "MIRVETUXIMAB SORAVTANSINE": { "n": 23, "n_observational": 2, "n_active": 13, "n_withdrawn": 0, "trials": [ { "nct": "NCT04606914", "title": "Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer", "status": "RECRUITING", "last_update": "2026-07-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05887609", "title": "An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib", "status": "RECRUITING", "last_update": "2026-07-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06682988", "title": "A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine", "status": "RECRUITING", "last_update": "2026-05-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06890338", "title": "A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FR\u03b1)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.", "status": "RECRUITING", "last_update": "2026-09-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07059845", "title": "A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer", "status": "RECRUITING", "last_update": "2026-08-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07213804", "title": "A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer", "status": "RECRUITING", "last_update": "2026-09-08", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07218809", "title": "AZD5335 vs. Mirvetuximab Soravtansine in FR\u03b1-high and AZD5335 vs. Chemotherapy in FR\u03b1-low Platinum-resistant Ovarian Cancer", "status": "RECRUITING", "last_update": "2026-07-21", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01609556", "title": "First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Mirvetuximab Soravtansine in Adults With Ovarian Cancer and Other Folate Receptor 1 (FOLR1)-Positive Solid Tumors", "status": "COMPLETED", "last_update": "2021-02-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02606305", "title": "Study of Mirvetuximab Soravtansine in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin in Participants With Folate Receptor Alpha (FR\u03b1) Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal, or Fallopian Tube Cancer", "status": "COMPLETED", "last_update": "2024-06-14", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02631876", "title": "A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer", "status": "COMPLETED", "last_update": "2020-10-14", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02996825", "title": "Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients With FRalpha-Positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial, or Triple Negative Breast Cancer", "status": "COMPLETED", "last_update": "2024-04-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03552471", "title": "Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer", "status": "COMPLETED", "last_update": "2025-02-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04209855", "title": "A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FR\u03b1) Expression", "status": "COMPLETED", "last_update": "2025-08-27", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04274426", "title": "Mirvetuximab Soravtansine (IMGN853), in Folate Receptor Alpha (FR\u03b1) High Recurrent Ovarian Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04296890", "title": "A Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression", "status": "COMPLETED", "last_update": "2024-08-07", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05041257", "title": "Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Peritoneal, and Fallopian Tube Cancers", "status": "COMPLETED", "last_update": "2026-01-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05445778", "title": "Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-02", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05456685", "title": "Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FR\u03b1) Expressing, Platinum-sensitive Epithelial Ovarian Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-10-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05483933", "title": "Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian Cancers", "status": "COMPLETED", "last_update": "2025-12-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05622890", "title": "A Single-arm Clinical Trial of IMGN853 in Chinese Adult Patients With Platinum-resistant, Epithelial Ovarian Cancer", "status": "UNKNOWN", "last_update": "2022-11-21", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06365853", "title": "A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06390995", "title": "A Study of TAK-853 in Adult Participants With Folate Receptor Alpha-Positive Advanced Ovarian Cancer And Other Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-16", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07741630", "title": "Mirvetuximab Soravtansine Combined With Suvemcitug in Platinum-Resistant Recurrent Ovarian Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "OMIPALISIB": { "n": 1, "n_observational": 0, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT02465060", "title": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "OREGOVOMAB": { "n": 16, "n_observational": 0, "n_active": 4, "n_withdrawn": 1, "trials": [ { "nct": "NCT00003634", "title": "Monoclonal Antibody Therapy in Treating Patients With Residual Disease From Stage III or Stage IV Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer Following Surgery and Chemotherapy", "status": "UNKNOWN", "last_update": "2013-11-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00004064", "title": "Monoclonal Antibody Therapy in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal Cancer", "status": "UNKNOWN", "last_update": "2013-11-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00034138", "title": "A Comparative Pharmacokinetics and Safety Study of OvaRex MAb-B43.13 in Patients With Ovarian Epithelial Carcinoma", "status": "TERMINATED", "last_update": "2007-12-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00034372", "title": "Multicenter Clinical Trial of Intravenous OvaRex MAb-B43.13 as Post-Chemotherapy Consolidation for Ovarian Carcinoma", "status": "TERMINATED", "last_update": "2007-12-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00050375", "title": "Clinical Trial for Ovarian Cancer (OvaRex\u00ae)", "status": "TERMINATED", "last_update": "2007-12-18", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00086632", "title": "Study of Ovarex\u00ae (Oregovomab) MAb With Front-Line Chemotherapy for Ovarian Cancer Treatment", "status": "TERMINATED", "last_update": "2007-12-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00551265", "title": "Oregovomab With or Without Cyclophosphamide in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Responded to Second-Line Chemotherapy", "status": "WITHDRAWN", "last_update": "2017-07-14", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01616303", "title": "A Controlled Study of the Effectiveness of Oregovomab (Antibody) Plus Chemotherapy in Advanced Ovarian Cancer", "status": "COMPLETED", "last_update": "2020-09-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03100006", "title": "Phase Ib/IIa Trial to Evaluate Oregovomab and Nivolumab in Epithelial Cancer of Ovarian, Tubal or Peritoneal Origin", "status": "TERMINATED", "last_update": "2022-06-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03162562", "title": "The Safety and Antitumor Activity of the Combination of Oregovomab and Hiltonol in Recurrent Advanced Ovarian Cancer", "status": "TERMINATED", "last_update": "2020-12-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04498117", "title": "Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-01", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04620954", "title": "Clinical Trial of Chemotherapy, Oregovomab and Nivolumab in Patients With Epithelial Cancer of Ovarian, Tubal or Peritoneal Origin", "status": "UNKNOWN", "last_update": "2021-12-01", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04938583", "title": "Oregovomab in Combination With Bevacizumab Plus Chemo in BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-06", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05335993", "title": "A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05407584", "title": "Oregovomab and PLD in PARP Inhibitor Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment", "status": "UNKNOWN", "last_update": "2023-05-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05605535", "title": "Oregovomab Plus Chemotherapy in Neo-adjuvant Setting in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "PILARALISIB": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT00756847", "title": "Safety Study of XL147 (SAR245408), in Combination With Paclitaxel and Carboplatin in Adults With Solid Tumors", "status": "COMPLETED", "last_update": "2013-04-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "SERABELISIB": { "n": 1, "n_observational": 0, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT06463028", "title": "Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer", "status": "RECRUITING", "last_update": "2025-12-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "SOTORASIB": { "n": 1, "n_observational": 0, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT05564377", "title": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial", "status": "RECRUITING", "last_update": "2026-09-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "SS1(DSFV)-PE38": { "n": 2, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT00006981", "title": "Immunotoxin Therapy in Treating Patients With Advanced Cancer", "status": "COMPLETED", "last_update": "2015-04-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00066651", "title": "Immunotoxin Therapy in Treating Patients With Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2015-04-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "TASELISIB": { "n": 1, "n_observational": 0, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT02465060", "title": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "VINTAFOLIDE": { "n": 3, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT00507741", "title": "Study of Vintafolide (MK-8109, EC145) in Participants With Advanced Ovarian and Endometrial Cancers (MK-8109-007, EC-FV-02)", "status": "COMPLETED", "last_update": "2015-01-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00722592", "title": "Platinum Resistant Ovarian Cancer Evaluation of Doxil and Vintafolide (MK-8109, EC145) Combination Therapy (8109-009, EC-FV-04)", "status": "COMPLETED", "last_update": "2015-01-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01170650", "title": "Study for Women With Platinum Resistant Ovarian Cancer Evaluating EC145 in Combination With Doxil\u00ae (PROCEED)", "status": "TERMINATED", "last_update": "2021-09-30", "phase": "PHASE3", "study_type": "INTERVENTIONAL" } ] }, "VOXTALISIB": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT01936363", "title": "Trial of Pimasertib With SAR245409 or Placebo in Ovarian Cancer", "status": "COMPLETED", "last_update": "2018-12-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] } } } }